Sulfadoxine
Fansidar (sulfadoxine) is a small molecule pharmaceutical. Sulfadoxine was first approved as Fansidar on 1982-01-01. It is used to treat falciparum malaria and pneumocystis pneumonia in the USA. It is known to target hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
178 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 9 | 18 | 55 | 32 | 51 | 152 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 5 | 11 | 7 | 12 | 33 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 5 | 6 | 14 | 25 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 5 | 3 | 5 | 14 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 3 | 1 | 3 | 7 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 2 | 1 | 2 | 6 |
| Birth weight | D001724 | EFO_0004344 | — | — | — | — | 2 | 2 | 4 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 1 | 1 | 1 | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | 1 | 1 | 3 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | 1 | — | 2 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | 1 | 2 | — | 2 | 5 |
| Parasitemia | D018512 | — | — | 1 | 1 | 1 | — | 1 | 4 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | 2 | — | — | 3 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | 2 | — | — | 2 |
| Only child | D009863 | — | — | — | — | 2 | — | — | 2 |
| Asymptomatic diseases | D058070 | — | — | — | — | 1 | — | — | 1 |
| Child mortality | D046688 | — | — | — | — | 1 | — | — | 1 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | — | 1 |
| Healthy volunteers/patients | — | — | — | — | — | 1 | — | — | 1 |
| Reproductive tract infections | D060737 | — | — | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | — | — | 2 | 3 |
| Vaso-occlusive crises | D000098644 | — | — | 1 | 1 | — | — | — | 1 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | — | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | — | — | — | — | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 1 | — | — | — | — | 1 |
| Lymphadenopathy | D000072281 | — | R59.1 | 1 | — | — | — | — | 1 |
| Splenomegaly | D013163 | — | R16.1 | 1 | — | — | — | — | 1 |
| Autoimmune lymphoproliferative syndrome | D056735 | — | D89.82 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 6 | 6 |
| Growth disorders | D006130 | — | — | — | — | — | — | 2 | 2 |
| Severe acute malnutrition | D000067011 | — | — | — | — | — | — | 2 | 2 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | — | 1 | 1 |
| Fever | D005334 | — | R50.9 | — | — | — | — | 1 | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | — | — | 1 | 1 |
| Behavior | D001519 | GO_0007610 | STY/T053 | — | — | — | — | 1 | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Child development | D002657 | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfadoxine |
| INN | sulfadoxine |
| Description | Sulfadoxine is a sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial. It has a role as an antibacterial drug and an antimalarial. It is a sulfonamide and a member of pyrimidines. |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC |
Identifiers
| PDB | — |
| CAS-ID | 2447-57-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1539 |
| ChEBI ID | 9329 |
| PubChem CID | 17134 |
| DrugBank | DB01299 |
| UNII ID | 88463U4SM5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Organism
Plasmodium falciparum 3D7
Gene name
Gene synonyms
NCBI Gene ID
Protein name
hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase
Protein synonyms
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,052 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
225 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use